Research and development spending of Starry Pharmaceutical 2021-2022
In 2022, the Chinese pharmaceutical firm Starry Pharmaceutical spent 132.6 million yuan on research and development, indicating a growth by 6.4 percent from the previous year. Although a relatively small company in the industry, Starry is one of the most important manufacturers of radiocontrast agents in China.